Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Muscle Nerve ; 64(5): 590-594, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34196979

RESUMO

INTRODUCTION/AIMS: Intracellular congophilic inclusions within muscle fibers, although nonspecific, are one of the pathological hallmarks of sporadic inclusion body myositis (sIBM). Extracellular amyloid deposits in muscle, on the other hand, are the canonical findings of amyloid myopathies, which occur with or without systemic amyloidosis. METHODS: We reviewed the muscle biopsy database (1998-2020) to identify sIBM patients with extracellular amyloid deposits. Clinical and laboratory data were reviewed. RESULTS: We identified five sIBM patients (three clinicopathologically defined and two clinically defined) with extracellular amyloid deposits in muscle. Mean age at diagnosis was 74.8 y (range, 68-84 y). All patients had a typical sIBM pattern of weakness without associated sensory or autonomic symptoms. None had electrophysiological evidence of peripheral neuropathy. Only one patient had a monoclonal gammopathy (immunoglobulin M-lambda, IgM-λ) with normal bone marrow biopsy. This patient with monoclonal gammopathy and three other patients underwent abdominal fat pad aspirate and were negative for amyloid. Cardiac evaluation was unrevealing in the four patients tested. Three patients without monoclonal gammopathy had normal transthyretin gene sequencing and inconclusive mass spectrometry-based analysis. The patient with monoclonal gammopathy died of pneumosepsis 5 y after diagnosis and autopsy revealed multi-organ transthyretin amyloidosis. DISCUSSION: Detection of extracellular amyloid deposition in muscle should trigger an aggressive search for systemic amyloidosis independently from other associated myopathological abnormalities. Amyloid subtyping is crucial for early therapy and mortality prevention. An isolated monoclonal gammopathy should not halt a search for non-hematological causes of systemic amyloidosis.


Assuntos
Neuropatias Amiloides Familiares , Amiloidose de Cadeia Leve de Imunoglobulina , Gamopatia Monoclonal de Significância Indeterminada , Miosite de Corpos de Inclusão , Amiloide , Humanos , Miosite de Corpos de Inclusão/complicações
2.
Curr Pain Headache Rep ; 25(5): 31, 2021 Mar 24.
Artigo em Inglês | MEDLINE | ID: mdl-33761012

RESUMO

PURPOSE OF REVIEW: Though first bite syndrome is well known in surgical settings, it is not commonly included in the differential for sharp paroxysmal facial pain in the neurology literature. This paper will highlight the clinical features and relevant anatomy of first bite syndrome, with the goal of helping clinicians differentiate this from other similar facial pain disorders. RECENT FINDINGS: First bite syndrome is severe sharp or cramping pain in the parotid region occurring with the first bite of each meal and improving with subsequent bites. Pathophysiology has been attributed to imbalanced sympathetic/parasympathetic innervation of the parotid gland. This is seen most typically in the post-surgical setting following surgery in the parotid or parapharyngeal region, but neoplastic etiologies have also been reported. It is common for patients to present with concurrent great auricular neuropathy and/or Horner's syndrome. Evidence regarding treatment is limited to case reports/series, however, botulinum toxin injections and neuropathic medicines have been helpful in select cases. It is critical for clinicians to be able to differentiate first bite syndrome from other paroxysmal facial pain. To help with this, we have proposed diagnostic criteria for clinical assessment. Patients often improve gradually over time, but symptomatic treatment with botulinum toxin or neuropathic medicine may be required.


Assuntos
Dor Facial/diagnóstico , Complicações Pós-Operatórias/diagnóstico , Inibidores da Liberação da Acetilcolina/uso terapêutico , Amitriptilina/análogos & derivados , Amitriptilina/uso terapêutico , Analgésicos não Narcóticos/uso terapêutico , Toxinas Botulínicas/uso terapêutico , Tumor do Corpo Carotídeo/cirurgia , Dor Facial/tratamento farmacológico , Dor Facial/etiologia , Dor Facial/fisiopatologia , Neoplasias de Cabeça e Pescoço/complicações , Neoplasias de Cabeça e Pescoço/cirurgia , Síndrome de Horner/complicações , Humanos , Relaxantes Musculares Centrais/uso terapêutico , Procedimentos Cirúrgicos Otorrinolaringológicos/efeitos adversos , Espaço Parafaríngeo , Glândula Parótida/inervação , Neoplasias Parotídeas/complicações , Complicações Pós-Operatórias/tratamento farmacológico , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/fisiopatologia , Carcinoma de Células Escamosas de Cabeça e Pescoço/cirurgia , Neoplasias Tonsilares/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA